Filing Flows › Biolargo (BLGO) › Q2 2026 › vs Q2 2025
Biolargo (BLGO) Q2 2026 vs Q2 2025 (year over year)
Biolargo's revenue fell $1.5M (-55%) from $2.8M in Q2 2025 to $1.2M in Q2 2026. The biggest changes: Product −$1.6M (-79%); Service +$56K (+7%).
Biolargo, Q2 2026: revenue $1.2M (-55% year over year), operating margin -298.7%, net loss $4.0M, operating cash flow −$3.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Service | $827K | $771K | $56K | +7% |
| Product | $421K | $2.0M | −$1.6M | -79% |
| Revenue | $1.2M | $2.8M | −$1.5M | -55% |
| Net loss | $4.0M | $1.9M | $2.1M | +113% |
| Costs & expenses | $5.2M | $4.7M | $589K | +13% |
| Operating costs | $5.0M | $4.6M | $397K | +9% |
| Interest & other, net | $272K | $80K | $192K | +240% |
| Cost of revenue | $573K | $1.4M | −$783K | -58% |
| Research & development | $1.1M | $535K | $553K | +103% |
| SG&A | $3.3M | $2.7M | $627K | +23% |
| Operating cash sources | $4.0M | $1.9M | $2.1M | +113% |
| Depreciation | $31K | $36K | −$5K | -14% |
| Share-based compensation | $722K | $492K | $230K | +47% |
| Working capital & other | $191K | −$764K | $955K | — |
| Cash used in operations | $3.1M | $2.1M | $938K | +44% |
| Net loss absorbed | $4.0M | $1.9M | $2.1M | +113% |
Questions
How much did Biolargo's revenue grow year over year in Q2 2026?
Biolargo's revenue fell $1.5M (-55%) from $2.8M in Q2 2025 to $1.2M in Q2 2026.
What drove Biolargo's revenue change in Q2 2026?
Product −$1.6M (-79%); Service +$56K (+7%).